Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review
Andrea Lombardi, Andrea Gramegna, Margherita Ori, Cecilia Azzarà, Francesco Blasi, Andrea Gori
Source: ERJ Open Res, 8 (4) 00364-2022; 10.1183/23120541.00364-2022
Abstract
Immune checkpoint inhibitors (ICIs) are drugs growingly employed in the treatment of cancers, but there are still uncertainties about their possible role in the risk of developing nontuberculous mycobacteria (NTM) infections. To understand this, we performed a systematic review of the literature including studies published between 20 June 2012 and 20 June 2022 which described the occurrence of NTM infections among patients treated with ICIs. Overall, we included seven studies describing nine patients with NTM infection occurring during ICIs therapy.
NTM infections occurring during ICIs therapy are mainly caused by germs belonging to the Mycobacterium avium complex, involve primarily the lungs, on average 1 year after the start of treatment, and are not associated with immunosuppressive treatments.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Andrea Lombardi, Andrea Gramegna, Margherita Ori, Cecilia Azzarà, Francesco Blasi, Andrea Gori. Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review. ERJ Open Res, 8 (4) 00364-2022; 10.1183/23120541.00364-2022
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|